Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Glioblastoma Multiforme: early-phase trial registry
1 of 7 indexed Recurrent Glioblastoma Multiforme trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Glioblastoma Multiforme: 7 US clinical trials tracked, 1 recruiting.
Recurrent Glioblastoma Multiforme is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is CASI pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-glioblastoma-multiforme
OPEN 1 | RECR 14% | LATE 1 | EARLY 6 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Recurrent Glioblastoma Multiforme lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Glioblastoma Multiforme on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Glioblastoma Multiforme is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Recurrent Glioblastoma Multiforme trials is spread across many organizations.
CASI pharmaceuticals accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Recurrent Glioblastoma Multiforme enrolment sits around 32 participants.
Median target enrolment is 32 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
Recurrent Glioblastoma Multiforme research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
NCT03423628
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
University of Alabama at Birmingham
NCT02062827
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
NovoCure
NCT00379470
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01576666
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Duke University
NCT00597493
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
CASI pharmaceuticals
NCT00481455
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Monteris Medical
NCT00747253
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Glioblastoma Multiforme records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Glioblastoma Multiforme trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Glioblastoma Multiforme page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Glioblastoma Multiforme trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- CASI pharmaceuticals sponsors the most Recurrent Glioblastoma Multiforme trials on record, review their full trial history before evaluating a specific study. See CASI pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Glioblastoma Multiforme condition card totals 7 registered trials; most-linked intervention NovoTTF-100A; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.